FIGURE 3.

Overview of the rationale to study chronic inflammatory exposure in THP‐1 myelo‐monocytic cells. (a) A conceptual model describing the nature of DNA methylation sites that are associated with the inflammatory biomarker C‐reactive protein (CRP), implicating both exogenous stressors and benign effectors. (b) Results from the eFORGE v2.0 cell signature analysis of the top 1000 CpG sites identified in the 2022 EWAS by Wielscher and colleagues; the prediction of different blood cell types [peripheral blood (PB) or cord blood leukocytes and female/male hematopoietic stem cells (HSCs) following GM‐CSF therapy] is based on FDR‐adjusted p‐value (i.e., q‐value) and the number of classified probes. (c) The design of the long‐term THP‐1 inflammatory exposure experiment.